Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

NASDAQ:ATRA - Nasdaq - US0465132068 - Common Stock - Currency: USD

7.52  -0.25 (-3.22%)

Premarket: 7.3 -0.22 (-2.93%)

Fundamental Rating

2

Taking everything into account, ATRA scores 2 out of 10 in our fundamental rating. ATRA was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of ATRA have multiple concerns. ATRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATRA has reported negative net income.
In the past year ATRA has reported a negative cash flow from operations.
ATRA had negative earnings in each of the past 5 years.
ATRA had a negative operating cash flow in each of the past 5 years.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -93.31%, ATRA is not doing good in the industry: 73.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -93.31%
ROE N/A
ROIC N/A
ROA(3y)-100.05%
ROA(5y)-87.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 82.70%, ATRA belongs to the top of the industry, outperforming 87.57% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ATRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

ATRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATRA has less shares outstanding
ATRA has less shares outstanding than it did 5 years ago.
The debt/assets ratio for ATRA is higher compared to a year ago.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

ATRA has an Altman-Z score of -22.52. This is a bad value and indicates that ATRA is not financially healthy and even has some risk of bankruptcy.
ATRA has a worse Altman-Z score (-22.52) than 87.74% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.52
ROIC/WACCN/A
WACC8.35%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

ATRA has a Current Ratio of 0.59. This is a bad value and indicates that ATRA is not financially healthy enough and could expect problems in meeting its short term obligations.
ATRA's Current ratio of 0.59 is on the low side compared to the rest of the industry. ATRA is outperformed by 92.72% of its industry peers.
A Quick Ratio of 0.50 indicates that ATRA may have some problems paying its short term obligations.
ATRA's Quick ratio of 0.50 is on the low side compared to the rest of the industry. ATRA is outperformed by 93.07% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.5
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.91% over the past year.
The Revenue has grown by 2107.45% in the past year. This is a very strong growth!
EPS 1Y (TTM)62.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.24%
Revenue 1Y (TTM)2107.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1779.79%

3.2 Future

ATRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.63% yearly.
The Revenue is expected to grow by 73.86% on average over the next years. This is a very strong growth
EPS Next Y96.53%
EPS Next 2Y36.29%
EPS Next 3Y25.45%
EPS Next 5Y14.63%
Revenue Next Year652.64%
Revenue Next 2Y142.42%
Revenue Next 3Y66.64%
Revenue Next 5Y73.86%

3.3 Evolution

ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as ATRA's earnings are expected to grow with 25.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.29%
EPS Next 3Y25.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (2/20/2025, 8:00:00 PM)

Premarket: 7.3 -0.22 (-2.93%)

7.52

-0.25 (-3.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners51.09%
Inst Owner Change-2.28%
Ins Owners2.05%
Ins Owner Change0.88%
Market Cap43.32M
Analysts78.33
Price Target13.52 (79.79%)
Short Float %15.91%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-71.58%
Min EPS beat(2)-94.51%
Max EPS beat(2)-48.64%
EPS beat(4)1
Avg EPS beat(4)-36.26%
Min EPS beat(4)-94.51%
Max EPS beat(4)12.03%
EPS beat(8)3
Avg EPS beat(8)-32.65%
EPS beat(12)5
Avg EPS beat(12)-18.39%
EPS beat(16)7
Avg EPS beat(16)-14.48%
Revenue beat(2)1
Avg Revenue beat(2)-8.87%
Min Revenue beat(2)-29.79%
Max Revenue beat(2)12.04%
Revenue beat(4)2
Avg Revenue beat(4)-18.26%
Min Revenue beat(4)-63.91%
Max Revenue beat(4)12.04%
Revenue beat(8)2
Avg Revenue beat(8)-49.95%
Revenue beat(12)4
Avg Revenue beat(12)15.82%
Revenue beat(16)6
Avg Revenue beat(16)15.05%
PT rev (1m)-18.88%
PT rev (3m)-85.36%
EPS NQ rev (1m)-38.93%
EPS NQ rev (3m)-2231.08%
EPS NY rev (1m)73.28%
EPS NY rev (3m)70.4%
Revenue NQ rev (1m)-26.53%
Revenue NQ rev (3m)-20.8%
Revenue NY rev (1m)-4.07%
Revenue NY rev (3m)7.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-25.78
EYN/A
EPS(NY)-9.34
Fwd EYN/A
FCF(TTM)-16.47
FCFYN/A
OCF(TTM)-16.43
OCFYN/A
SpS17.44
BVpS-15.72
TBVpS-15.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.7%
FCFM N/A
ROA(3y)-100.05%
ROA(5y)-87.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.86%
Cap/Sales 0.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.5
Altman-Z -22.52
F-Score4
WACC8.35%
ROIC/WACCN/A
Cap/Depr(3y)70.88%
Cap/Depr(5y)69.57%
Cap/Sales(3y)24.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.24%
EPS Next Y96.53%
EPS Next 2Y36.29%
EPS Next 3Y25.45%
EPS Next 5Y14.63%
Revenue 1Y (TTM)2107.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1779.79%
Revenue Next Year652.64%
Revenue Next 2Y142.42%
Revenue Next 3Y66.64%
Revenue Next 5Y73.86%
EBIT growth 1Y59.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.37%
EBIT Next 3Y14.18%
EBIT Next 5Y8.28%
FCF growth 1Y62.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.81%
OCF growth 3YN/A
OCF growth 5YN/A